《大行》高盛升再鼎医药(09688.HK)目标价至42.01元评级“买入”

阿斯达克财经

2025/03/03

高盛发表研究报告指，再鼎医药(09688.HK) (ZLAB.US) 2024年第四季销售表现符合预期，收入按年增长66%至1.085亿美元，符合该行预期的1.08亿美元，各项产品收入表现均符合高盛预测，相信公司去年优化商业团队所带来的短期影响已消散，预测2025财年艾加莫德(Efgartigimod)收入将达到10亿元人民币，重申2025年是再鼎医药发展里程碑年，亏损预期将持续收窄，预计至今年...

网页链接

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2516493579"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2516493579\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2516493579?lang=zh_CN&edition=fundamental","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20230802095625943_s.jpg","is_english":false,"pubTime":"2025-03-03 12:24","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2516493579","market":"sh","top_or_hot":-1,"title":"《大行》高盛升再鼎医药(09688.HK)目标价至42.01元 评级“买入”","media":"阿斯达克财经","content":"<div>\n<p>高盛发表研究报告指，再鼎医药(09688.HK) (ZLAB.US)  2024年第四季销售表现符合预期，收入按年增长66%至1.085亿美元，符合该行预期的1.08亿美元，各项产品收入表现均符合高盛预测，相信公司去年优化商业团队所带来的短期影响已消散，预测2025财年艾加莫德(Efgartigimod)收入将达到10亿元人民币，重申2025年是再鼎医药发展里程碑年，亏损预期将持续收窄，预计至今年...</p>\n\n<a href=\"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1421573/latest-news/AAFN\">网页链接</a>\n\n</div>\n","source":"aastocks_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>《大行》高盛升再鼎医药(09688.HK)目标价至42.01元 评级“买入”</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n《大行》高盛升再鼎医药(09688.HK)目标价至42.01元 评级“买入”\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-03-03 12:24 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1421573/latest-news/AAFN><strong>阿斯达克财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>高盛发表研究报告指，再鼎医药(09688.HK) (ZLAB.US)  2024年第四季销售表现符合预期，收入按年增长66%至1.085亿美元，符合该行预期的1.08亿美元，各项产品收入表现均符合高盛预测，相信公司去年优化商业团队所带来的短期影响已消散，预测2025财年艾加莫德(Efgartigimod)收入将达到10亿元人民币，重申2025年是再鼎医药发展里程碑年，亏损预期将持续收窄，预计至今年...</p>\n\n<a href=\"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1421573/latest-news/AAFN\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"09688","symbol_name":"再鼎医药","start_time":0,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1421573/latest-news/AAFN","article_id":"2516493579","we_media_id":null,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20230802095625943_s.jpg"],"rights":{"source":"aastocks_highlight","url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1421573/latest-news/AAFN","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2516493579","pubTimestamp":1740975840,"columns":[],"sourceInfo":{"source_id":"aastocks_highlight","name":"阿思達克財經"},"weMediaInfo":null,"summary":"高盛将再鼎医药2025至2026年每股亏损预测从原先各2美元及0.4美元，调整至每股亏损各1.6美元及0.3美元，H股目标价从40.4港元上调至42.01港元。(港股报价延迟最少十五分钟。沽空资料截至 2025-03-03 12:25。) (美股为即时串流报价； OTC市场股票除外，资料延迟最少15分钟。","collect":0,"end_time":0,"defaultTopTitle":"aastocks.com","property":["rate"],"viewcount":null,"language":"zh","relate_stocks":{"09688":"再鼎医药"},"translate_title":"\"Big Bank\" Goldman Sachs raises Zai Lab (09688. HK) target price to 42.01 yuan, rating \"buy\"","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"09688":1},"content_text":"高盛发表研究报告指，再鼎医药(09688.HK) (ZLAB.US)  2024年第四季销售表现符合预期，收入按年增长66%至1.085亿美元，符合该行预期的1.08亿美元，各项产品收入表现均符合高盛预测，相信公司去年优化商业团队所带来的短期影响已消散，预测2025财年艾加莫德(Efgartigimod)收入将达到10亿元人民币，重申2025年是再鼎医药发展里程碑年，亏损预期将持续收窄，预计至今年第四季可实现盈利，关注bemarituzumab、TIVDAK及Optune等产品的新药上市申请进展，给予“买入”评级。高盛将再鼎医药2025至2026年每股亏损预测从原先各2美元及0.4美元，调整至每股亏损各1.6美元及0.3美元，H股目标价从40.4港元上调至42.01港元。(gc/da)(港股报价延迟最少十五分钟。沽空资料截至 2025-03-03 12:25。) (美股为即时串流报价； OTC市场股票除外，资料延迟最少15分钟。)AASTOCKS新闻","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}

《大行》高盛升再鼎医药(09688.HK)目标价至42.01元 评级“买入”

热议股票

《大行》高盛升再鼎医药(09688.HK)目标价至42.01元评级“买入”